Hercules Pharmaceuticals

Hercules is engaged in the development of pioneering, oral medication treatments for the management of cancer and viral infections, achieved through the inhibition of the Aryl Hydrocarbon Receptor (AhR). Hercules has verified that obstructing the Aryl Hydrocarbon Receptor has the potential to: augment the immune system's reaction to cancer diminish tumor development in various solid tumor models potentially be combined to amplify the effectiveness of other immuno-oncology medications.